Post‐transplant lymphoproliferative disease in children, adolescents, and young adults
Thomas G. Gross, Jeremy D. Rubinstein
Abstract
Post-transplant lymphoproliferative disease (PTLD) remains a major complication of transplantation. PTLD is a rare entity and very heterogenous making consensus on diagnosis and treatment very challenging. The majority are Epstein-Barr virus (EBV) driven, CD20+ B-cell proliferations. PTLD does occur following hematopoietic stem cell transplant (HSCT), but due to the relative short risk period and efficacy of pre-emptive therapy, PTLD following HSCT will not be discussed in this review. This review will focus on the epidemiology, role of EBV, clinical presentation, diagnosis and evaluation and the current and emerging treatment strategies for pediatric PTLD following solid organ transplantation.
Topics & Concepts
Lymphoproliferative diseaseMedicineHematopoietic stem cell transplantationDiseaseLymphoproliferative disordersEpidemiologyTransplantationPediatricsComplicationImmunologyYoung adultLymphomaIntensive care medicineInternal medicineViral-associated cancers and disordersPolyomavirus and related diseasesLymphoma Diagnosis and Treatment